Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012

Keizo Yamaguchi; Yoshikazu Ishii; Kazuhiro Tateda; Chikara Shimizu; Akira Suwabe; Mitsuo Kaku; Akira Hishinuma; Shigefumi Maesaki; Mitsuru Murata; Tetsuya Matsumoto; Hinako Murakami; Yoshihito Otsuka; Masato Maekawa; Tetsuya Yagi; Yuka Yamagishi; Shinichi Fujita; Yukio Hida; Kaname Nakatani; Satoshi Ichiyama; Ikuko Fujimoto; Hisashi Kohno; Kazuyuki Okuda; Nobuchika Kusano; Yukinori Kurokawa; Yaeko Watanabe; Kiyoshi Negayama; Hitoshi Miyamoto; Makiko Kiyosuke; Kouichi Mashiba; Katsunori Yanagihara; Yosuke Aoki; Kazufumi Hiramatsu

Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012

Keizo Yamaguchi, Yoshikazu Ishii, Kazuhiro Tateda, Chikara Shimizu, Akira Suwabe, Mitsuo Kaku, Akira Hishinuma, Shigefumi Maesaki, Mitsuru Murata, Tetsuya Matsumoto, Hinako Murakami, Yoshihito Otsuka, Masato Maekawa, Tetsuya Yagi, Yuka Yamagishi, Shinichi Fujita, Yukio Hida, Kaname Nakatani, Satoshi Ichiyama, Ikuko FujimotoHisashi Kohno, Kazuyuki Okuda, Nobuchika Kusano, Yukinori Kurokawa, Yaeko Watanabe, Kiyoshi Negayama, Hitoshi Miyamoto, Makiko Kiyosuke, Kouichi Mashiba, Katsunori Yanagihara, Yosuke Aoki, Kazufumi Hiramatsu

Department of Laboratory Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin (TAZ/PIPC) in 3,952 bacterial strains isolated in 2012 were conducted in Japan. β-lactamase production was investigated in over 80% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Providencia spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group. Extended spectrum β-lactamase-producing strains in E. coli, K. pneumoniae and P. mirabilis were 19.0%, 7.2% and 8.2%, respectively. Metallo-β-lactamase producers in P. aeruginosa and Acinetobacter spp. were 1.0% and 0.4%, respectively, and no strain of E. cloacae and S. marcescens was detected. Susceptibility of 3,952 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute or European Committee on Antimicrobial Susceptibility testing were distributed from 79.2% in E.cloacae to 100% in methicillin-susceptible S. aureus, coagulase-negative staphylococci, M. catarrhalis, P. mirabilis, indole-positive Proteus spp. and H. influenzae including β-lactamase-negative ampicillin-resistant strains. When compared with those in previous investigations conducted in 2010, the susceptibility to TAZ/PIPC had not changed. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for infectious diseases.

Original language	English
Pages (from-to)	668-680
Number of pages	13
Journal	Japanese Journal of Chemotherapy
Volume	64
Issue number	4
Publication status	Published - 2016 Jul

Keywords

CLSI
EUCAST
Susceptibility
Tazobactam/piperacillin
β-lactamase

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Yamaguchi, K., Ishii, Y., Tateda, K., Shimizu, C., Suwabe, A., Kaku, M., Hishinuma, A., Maesaki, S., Murata, M., Matsumoto, T., Murakami, H., Otsuka, Y., Maekawa, M., Yagi, T., Yamagishi, Y., Fujita, S., Hida, Y., Nakatani, K., Ichiyama, S., ... Hiramatsu, K. (2016). Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012. Japanese Journal of Chemotherapy, 64(4), 668-680.

Yamaguchi, K, Ishii, Y, Tateda, K, Shimizu, C, Suwabe, A, Kaku, M, Hishinuma, A, Maesaki, S, Murata, M, Matsumoto, T, Murakami, H, Otsuka, Y, Maekawa, M, Yagi, T, Yamagishi, Y, Fujita, S, Hida, Y, Nakatani, K, Ichiyama, S, Fujimoto, I, Kohno, H, Okuda, K, Kusano, N, Kurokawa, Y, Watanabe, Y, Negayama, K, Miyamoto, H, Kiyosuke, M, Mashiba, K, Yanagihara, K, Aoki, Y & Hiramatsu, K 2016, 'Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012', Japanese Journal of Chemotherapy, vol. 64, no. 4, pp. 668-680.

@article{9d3f97a54c1340cea8719bfed5b6136d,

title = "Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012",

abstract = "Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin (TAZ/PIPC) in 3,952 bacterial strains isolated in 2012 were conducted in Japan. β-lactamase production was investigated in over 80% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Providencia spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group. Extended spectrum β-lactamase-producing strains in E. coli, K. pneumoniae and P. mirabilis were 19.0%, 7.2% and 8.2%, respectively. Metallo-β-lactamase producers in P. aeruginosa and Acinetobacter spp. were 1.0% and 0.4%, respectively, and no strain of E. cloacae and S. marcescens was detected. Susceptibility of 3,952 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute or European Committee on Antimicrobial Susceptibility testing were distributed from 79.2% in E.cloacae to 100% in methicillin-susceptible S. aureus, coagulase-negative staphylococci, M. catarrhalis, P. mirabilis, indole-positive Proteus spp. and H. influenzae including β-lactamase-negative ampicillin-resistant strains. When compared with those in previous investigations conducted in 2010, the susceptibility to TAZ/PIPC had not changed. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for infectious diseases.",

keywords = "CLSI, EUCAST, Susceptibility, Tazobactam/piperacillin, β-lactamase",

author = "Keizo Yamaguchi and Yoshikazu Ishii and Kazuhiro Tateda and Chikara Shimizu and Akira Suwabe and Mitsuo Kaku and Akira Hishinuma and Shigefumi Maesaki and Mitsuru Murata and Tetsuya Matsumoto and Hinako Murakami and Yoshihito Otsuka and Masato Maekawa and Tetsuya Yagi and Yuka Yamagishi and Shinichi Fujita and Yukio Hida and Kaname Nakatani and Satoshi Ichiyama and Ikuko Fujimoto and Hisashi Kohno and Kazuyuki Okuda and Nobuchika Kusano and Yukinori Kurokawa and Yaeko Watanabe and Kiyoshi Negayama and Hitoshi Miyamoto and Makiko Kiyosuke and Kouichi Mashiba and Katsunori Yanagihara and Yosuke Aoki and Kazufumi Hiramatsu",

year = "2016",

month = jul,

language = "English",

volume = "64",

pages = "668--680",

journal = "Japanese Journal of Chemotherapy",

issn = "1340-7007",

publisher = "Japan Society of Chemotherapy",

number = "4",

}

TY - JOUR

T1 - Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012

AU - Yamaguchi, Keizo

AU - Ishii, Yoshikazu

AU - Tateda, Kazuhiro

AU - Shimizu, Chikara

AU - Suwabe, Akira

AU - Kaku, Mitsuo

AU - Hishinuma, Akira

AU - Maesaki, Shigefumi

AU - Murata, Mitsuru

AU - Matsumoto, Tetsuya

AU - Murakami, Hinako

AU - Otsuka, Yoshihito

AU - Maekawa, Masato

AU - Yagi, Tetsuya

AU - Yamagishi, Yuka

AU - Fujita, Shinichi

AU - Hida, Yukio

AU - Nakatani, Kaname

AU - Ichiyama, Satoshi

AU - Fujimoto, Ikuko

AU - Kohno, Hisashi

AU - Okuda, Kazuyuki

AU - Kusano, Nobuchika

AU - Kurokawa, Yukinori

AU - Watanabe, Yaeko

AU - Negayama, Kiyoshi

AU - Miyamoto, Hitoshi

AU - Kiyosuke, Makiko

AU - Mashiba, Kouichi

AU - Yanagihara, Katsunori

AU - Aoki, Yosuke

AU - Hiramatsu, Kazufumi

PY - 2016/7

Y1 - 2016/7

N2 - Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin (TAZ/PIPC) in 3,952 bacterial strains isolated in 2012 were conducted in Japan. β-lactamase production was investigated in over 80% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Providencia spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group. Extended spectrum β-lactamase-producing strains in E. coli, K. pneumoniae and P. mirabilis were 19.0%, 7.2% and 8.2%, respectively. Metallo-β-lactamase producers in P. aeruginosa and Acinetobacter spp. were 1.0% and 0.4%, respectively, and no strain of E. cloacae and S. marcescens was detected. Susceptibility of 3,952 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute or European Committee on Antimicrobial Susceptibility testing were distributed from 79.2% in E.cloacae to 100% in methicillin-susceptible S. aureus, coagulase-negative staphylococci, M. catarrhalis, P. mirabilis, indole-positive Proteus spp. and H. influenzae including β-lactamase-negative ampicillin-resistant strains. When compared with those in previous investigations conducted in 2010, the susceptibility to TAZ/PIPC had not changed. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for infectious diseases.

AB - Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin (TAZ/PIPC) in 3,952 bacterial strains isolated in 2012 were conducted in Japan. β-lactamase production was investigated in over 80% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Providencia spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group. Extended spectrum β-lactamase-producing strains in E. coli, K. pneumoniae and P. mirabilis were 19.0%, 7.2% and 8.2%, respectively. Metallo-β-lactamase producers in P. aeruginosa and Acinetobacter spp. were 1.0% and 0.4%, respectively, and no strain of E. cloacae and S. marcescens was detected. Susceptibility of 3,952 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute or European Committee on Antimicrobial Susceptibility testing were distributed from 79.2% in E.cloacae to 100% in methicillin-susceptible S. aureus, coagulase-negative staphylococci, M. catarrhalis, P. mirabilis, indole-positive Proteus spp. and H. influenzae including β-lactamase-negative ampicillin-resistant strains. When compared with those in previous investigations conducted in 2010, the susceptibility to TAZ/PIPC had not changed. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for infectious diseases.

KW - CLSI

KW - EUCAST

KW - Susceptibility

KW - Tazobactam/piperacillin

KW - β-lactamase

UR - http://www.scopus.com/inward/record.url?scp=84982293231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982293231&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84982293231

SN - 1340-7007

VL - 64

SP - 668

EP - 680

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

IS - 4

ER -

Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this